Senarai ini adalah analisis berdasarkan peristiwa pasaran terkini. Ia bukan cadangan pelaburan.
Perihal
Trillium Therapeutics Inc., a clinical stage immuno-oncology company, develops therapies for the treatment of cancer. Its include TTI-622, a SIRPa-IgG4 Fc fusion protein that is designed to enhance macrophage-mediated phagocytosis and anti-tumor activity by blocking the CD47, which is in Phase 1 clinical trials; and TTI-621, a SIRPa-IgG1 Fc fusion protein, which is in Phase 1 clinical trials and generates a signal blocking the CD47 for advanced relapsed or refractory hematologic malignancies, and solid tumors and mycosis fungoides. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was incorporated in 2004 is based in Mississauga, Canada.
Show more...
CEO
Dr. Jan Skvarka
Pekerja
33
Negara
CA
Penyenaraian
0 Comments
Kongsi pendapat anda
FAQ
Berapakah harga saham Trillium Therapeutics hari ini?▼
Harga semasa TRIL.TO ialah C$23.33 CAD — telah meningkat sebanyak +0.47% dalam 24 jam yang lalu. Pantau prestasi harga saham Trillium Therapeutics dengan lebih dekat pada carta.
Apakah simbol saham Trillium Therapeutics?▼
Bergantung pada bursa, simbol saham mungkin berbeza. Sebagai contoh, di bursa , saham Trillium Therapeutics didagangkan di bawah simbol TRIL.TO.
Berapa ramai pekerja yang dimiliki oleh Trillium Therapeutics?▼
Sehingga April 02, 2026, syarikat mempunyai 33 pekerja.
Trillium Therapeutics terletak dalam sektor apa?▼
Trillium Therapeutics beroperasi dalam sektor Healthcare.